Risk of Stroke and Death in Atrial Fibrillation by Type of Anticoagulation: A Propensity‐Matched Analysis

By  

PACING AND CLINICAL ELECTROPHYSIOLOGY, Vol. 38, Iss. 11, 2015-11 ,pp. : 1310-1316

John Wiley & Sons Inc

Access to resources Recommend Favorite

Characteristics of patients with non-valvular atrial fibrillation using dabigatran or warfarin in the US

By Schoof Nils   Schnee Janet   Schneider Gary   Gawlik Melissa   Zint Kristina   Clemens Andreas   Bartels Dorothee B.  

Current Medical Research and Opinion, Vol. 30, Iss. 5, 2014-05 ,pp. : 795-804

Informa Healthcare

Access to resources Recommend Favorite

Anticoagulation in patients with non-valvular atrial fibrillation: an evaluation of stability and early factors that predict longer-term stability on warfarin in a large UK population

By Currie Craig J.   McEwan Phil   Emmas Cathy   Morgan Christopher Ll.   Peters John R.  

Current Medical Research and Opinion, Vol. 21, Iss. 12, 2005-12 ,pp. : 1905-1913

Informa Healthcare

Access to resources Recommend Favorite

Hospital length of stay: is rivaroxaban associated with shorter inpatient stay compared to warfarin among patients with non-valvular atrial fibrillation?

By Laliberté François   Pilon Dominic   Raut Monika K.   Nelson Winnie W.   Olson William H.   Germain Guillaume   Schein Jeff R.   Lefebvre Patrick  

Current Medical Research and Opinion, Vol. 30, Iss. 4, 2014-04 ,pp. : 645-653

Informa Healthcare

Access to resources Recommend Favorite

Application of randomized clinical trial data to actual practice: apixaban therapy for reduction of stroke risk in non-valvular atrial fibrillation patients

By Amin Alpesh   Stokes Michael   Wu Ning   Gatt Elyse   Makenbaeva Dinara   Wiederkehr Daniel   Boulanger Luke  

Current Medical Research and Opinion, Vol. 29, Iss. 10, 2013-10 ,pp. : 1253-1261

Informa Healthcare

Access to resources Recommend Favorite